By Jennifer Boggs Managing Editor For companies working in orphan diseases, support from patient advocacy groups and foundations is critical, both in terms of providing…

Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia Mechelen, Belgium; 20 May 2010 – Galapagos NV (Euronext: GLPG) announced today that it…

$2.45 Million Will Fund Research and Product Development Program PORTLAND, Ore., & SOUTH EGREMONT, Mass.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII), and Charley’s Fund, Inc., today announced…